Chunk #14 — 3. Pharmacogenetic Studies of Treatment for Alcohol Use Disorder in Individuals of Diverse Ancestries — 3.1 Individuals of European Ancestry
than predicted, namely that NTX would reduce heavy drinking in this group.30 In addition to NTX, other medications have been examined to understand their influence on treatment response in Asp40 carriers. For example, a pharmacogenetic study examining the effect of nalmefene in Finnish AD individuals who carried the Asp40 allele, found no significant relationship between the G allele and treatment outcomes.37 It is clear that further studies are needed to clarify the relationship between response to medications and the OPRM1 Asn40Asp SNP as both positive and negative findings have been reported across multiple studies. Greater standardization of outcome measures across clinical trials will be needed to understand if findings from previously investigated gene-by-treatment interactions can be more consistently replicated.
